
Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Biomea Fusion and keeping the price target at $4.00. Joseph Pantginis has given his Buy rating due to a
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BMEA | Biomea Fusion | 0.57 | -0.41 | -41.55% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.57 | -41.55% |

Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Biomea Fusion and keeping the price target at $4.00. Joseph Pantginis has given his Buy rating due to a

Yigal Nochomovitz, an analyst from Citi, maintained the Buy rating on Biomea Fusion. The associated price target remains the same with $7.00. Yigal Nochomovitz’s rating is based on several factors,

“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance

Biomea Fusion Inc (BMEA) is scheduled to report 3rd quarter earnings on 11/03/2026. Regarding Q3 estimates, Wall Street analysts expect Biomea Fusion Inc to post earnings of -$0.21 per share.

Biomea Fusion ( ($BMEA) ) just unveiled an announcement. On October 13, 2026, Biomea Fusion hosted a conference call and webcast to present topline results from its ongoing Phase 1

The yield on the 10-year Treasury note slipped below 5.2% for the first time in nearly two weeks on Tuesday, and yet sentiment in equities remained cautious, with little support

Biomea Fusion (BMEA) announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist, or GLP-1 RA”, which demonstrated consistent weight reduction across five

Brookline analyst Kumaraguru Raja initiated coverage of Biomea Fusion (BMEA) with a Buy rating and $10 price target Biomea is developing icovamenib as a potentially disease-modifying therapy that can slow

Latest data shows the largest indicative borrow rate increases among liquid option names include: Arbutus Biopharma (ABUS) 36.19% +33.17, Biomea Fusion (BMEA) 4.23% +2.82, Campbell Soup (CPB) 15.28% +1.36, Aries

Latest data shows the largest indicative borrow rate increases among liquid option names include: FingerMotion (FNGR) 28.95% +3.80, Securitize Corp. (SECZ) 28.91% +2.64, Biomea Fusion (BMEA) 3.26% +1.83, Vail Resorts
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 30, 2027TBA | $42.76M | $-0.21 | $0.00 | 0.02 | -1.82 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.